Your browser doesn't support javascript.
loading
Stress Ulcer Prophylaxis in Mechanically Ventilated Patients With Acute Myocardial Infarction.
Banna, Soumya; Schenck, Christopher; Shahu, Andi; Thomas, Alexander; Heck, Cory; Tangredi, Rosanna; Ali, Tariq; Miller, P Elliott.
  • Banna S; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Schenck C; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Shahu A; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Thomas A; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Heck C; Heart and Vascular Medicine, Yale New Haven Hospital, New Haven, Connecticut, USA.
  • Tangredi R; Heart and Vascular Medicine, Yale New Haven Hospital, New Haven, Connecticut, USA.
  • Ali T; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Miller PE; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
JACC Adv ; 3(1): 100750, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38939822
ABSTRACT

Background:

Proton pump inhibitors (PPIs) and histamine type 2-receptor blockers (H2Bs) are commonly used for stress ulcer prophylaxis among patients requiring invasive mechanical ventilation (IMV). Recent studies suggest an increased mortality associated with PPIs compared to H2Bs, but these studies poorly represent patients with cardiovascular disease or acute myocardial infarction (AMI).

Objectives:

The aim of this study was to compare outcomes related to stress ulcer prophylaxis with PPIs compared to H2Bs in patients with AMI requiring IMV.

Methods:

We queried the Vizient Clinical Data Base for adults aged ≥18 years admitted between October 2015 and December 2019 with a primary diagnosis of AMI and requiring IMV. Using multivariable logistic regression, we assessed for the association between stress ulcer prophylaxis and in-hospital mortality.

Results:

Including 11,252 patients with AMI requiring IMV, 66.7% (n = 7,504) received PPIs and 33.3% (n = 3,748) received H2Bs. Age, sex, and the proportion of patients presenting with ST-segment elevation myocardial infarction or cardiogenic shock were similar between groups (all, P > 0.05). Compared to PPIs, patients receiving H2Bs had a lower mortality (41.5% vs 43.5%, P = 0.047), which was not statistically significant after multivariate adjustment (odds ratio 0.97; 95% confidence interval 0.89-1.06, P = 0.49). In unadjusted and adjusted analyses, H2Bs use was associated with fewer ventilator days, less ventilator-associated pneumonia, and lower hospitalization cost but similar Clostridium difficile infections.

Conclusions:

Among patients with AMI requiring IMV in this observation cohort study, there was no difference in mortality among patients receiving H2Bs vs PPIs for stress ulcer prophylaxis despite fewer ventilator days and lower ventilator-associated pneumonia in those receiving H2Bs.
Palabras clave